🔍 Observations
Topline
- FY26 revenue grew 3% YoY (₹325,535 Mn → ₹335,933 Mn); Q4FY26 dropped 12% YoY and 14% QoQ to ₹75,162 Mn — the weakest quarter of the year.
- North America collapsed 51% YoY in Q4 (₹35,586 Mn → ₹17,562 Mn) and 22% for full FY26 — a structural drag that erased gains elsewhere.
- Europe (+55% FY26 YoY) and Emerging Markets (+23%) partially offset the North America erosion; India grew a solid 16% to ₹62,186 Mn.
Bottomline
- FY26 net profit fell 26% YoY (₹57,245 Mn → ₹42,466 Mn); Q4FY26 net profit of ₹2,205 Mn was 86% below Q4FY25 (₹15,873 Mn).
- Q4 tax line shows a net credit of ₹214 Mn (vs. expense of ₹4,181 Mn in Q4FY25), suggesting deferred tax reversals propped up an otherwise near-zero operating quarter.
- Basic EPS declined from ₹67.88 to ₹51.48 for FY26; Q4 EPS of ₹2.64 vs. ₹19.13 a year ago underscores the severity of the Q4 drop.
Margins
- FY26 gross margin compressed to 52.8% (₹177,264 Mn / ₹335,933 Mn) from 58.5% in FY25 — a 570 bps erosion driven by cost of revenues rising 17% while revenue grew only 3%.
- PSAI segment gross profit fell 35% YoY (₹9,157 Mn → ₹5,984 Mn) on a revenue decline of just 3% — margin collapse within the segment is severe.
- Operating profit (Results from operating activities) dropped 30% YoY (₹71,843 Mn → ₹50,551 Mn); Q4 operating profit of ₹1,325 Mn vs. ₹17,647 Mn in Q4FY25 — an 92% collapse.
Growth Trajectory
- Revenue CAGR is nominal at 3% for FY26; the geographic mix shift away from high-margin North America toward Emerging Markets and Europe changes the structural profitability profile.
- R&D spend fell 12% YoY (₹27,380 Mn → ₹24,058 Mn) — pipeline investment is declining even as the company faces revenue headwinds; raises medium-term concern.
- SG&A rose 14% YoY (₹93,870 Mn → ₹106,763 Mn) against 3% revenue growth — operating leverage is working in reverse.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- Operating cash flow surged 22% YoY (₹46,428 Mn → ₹56,755 Mn) despite lower profits — working capital discipline partially offset the earnings decline.
- Europe grew 55% YoY to ₹55,501 Mn — a fast-scaling geography diversifying away from North America concentration risk.
- India franchise up 16% YoY to ₹62,186 Mn — domestic branded generics provide a stable, recurring revenue base insulated from US pricing pressure.
- Emerging Markets grew 23% YoY to ₹67,608 Mn — the fastest-growing large segment, signalling geographic expansion momentum.
- Net cash (investments + cash) position is strong: Cash of ₹15,368 Mn + Other investments of ₹72,446 Mn (current) + ₹10,695 Mn (non-current) = ₹98,509 Mn vs. total borrowings of ₹77,341 Mn — net investment surplus remains positive.
- Intangible asset base expanding: Other intangible assets grew from ₹96,803 Mn to ₹105,059 Mn, reflecting licensed product pipeline additions that can monetise over time.
🔴 Red Flags
- North America revenue halved in Q4FY26 (₹35,586 Mn → ₹17,562 Mn YoY); full-year decline of 22% signals either pricing erosion, product exits, or competitive loss — not a one-quarter anomaly.
- Gross margin contracted 570 bps YoY — cost of revenues rose 17% on 3% revenue growth; no operating leverage in the model currently.
- PSAI segment margin collapsed: Gross profit fell 35% on a 3% revenue decline — implies sharp input cost pressures or product mix deterioration within the segment.
- Short-term borrowings jumped 55% (₹38,045 Mn → ₹59,135 Mn); combined with rising intangible and capex spend, the balance sheet is taking on more near-term refinancing risk.
- Impairment of non-current assets doubled (₹1,693 Mn → ₹3,519 Mn FY26) — signals product or asset write-downs are accelerating; Q4 alone contributed ₹2,586 Mn.
- SG&A growing faster than revenue for two consecutive years — structural cost inflation with no clear path to operating leverage unless topline reaccelerates meaningfully.
- Inventory write-downs of ₹7,517 Mn in FY26 (vs. ₹5,220 Mn in FY25) — rising obsolescence or demand shortfalls in certain product lines.
📊 Balance Sheet Analysis
- Total assets grew 18% (₹492,989 Mn → ₹579,346 Mn) but liabilities grew faster at 28% (₹155,823 Mn → ₹198,889 Mn) — mild leverage creep underway.
- Current ratio: ₹301,975 Mn / ₹167,566 Mn = 1.80x — adequate liquidity, but the spike in short-term borrowings (₹59,135 Mn) warrants monitoring against the FY25 level of ₹38,045 Mn.
- Trade receivables grew 12% (₹90,420 Mn → ₹101,219 Mn) on 3% revenue growth — receivables are growing disproportionately; collection cycle elongating.
- Equity base remains solid at ₹380,457 Mn with retained earnings of ₹351,984 Mn; debt-to-equity at (₹77,341 Mn / ₹380,457 Mn) = 0.20x — leverage is manageable but directionally rising.
💰 Cash Flow Analysis
- Operating cash flow of ₹56,755 Mn (FY26) vs. profit of ₹42,466 Mn — quality of earnings is high; D&A of ₹20,605 Mn and working capital partially absorbed the gap.
- Free cash flow: Operating CF ₹56,755 Mn minus capex ₹23,326 Mn minus intangible purchases ₹15,099 Mn = ₹18,330 Mn — down sharply from a FCF-implied figure in FY25 given higher intangible acquisitions (₹15,099 Mn vs. ₹6,894 Mn).
- Investing outflows of ₹65,513 Mn exceeded operating inflows of ₹56,755 Mn — the gap was plugged by ₹20,257 Mn in net short-term borrowings, explaining the balance sheet leverage build.
- Dividends paid of ₹6,659 Mn remain stable; the financing mix (more debt, less equity) signals management is stretching the balance sheet to fund inorganic and intangible growth.
💡 Investment Outlook
Dr. Reddy’s FY26 is a tale of a business under structural stress — North America, historically the highest-margin engine, contracted 22% for the full year and cratered 51% in Q4, dragging consolidated profitability despite resilient growth in Europe, India, and Emerging Markets.
Gross margin compression of 570 bps alongside SG&A inflation running well ahead of revenue signals the operating model needs either a North America recovery or a sustained acceleration in other geographies to restore earnings power.
The FCF base (₹18,330 Mn) remains positive and operating cash conversion is strong, but rising short-term borrowings and accelerating impairments are early warning signals that merit close monitoring.
Re-rating will hinge on North America stabilisation — absent that, earnings trajectory remains challenged through FY27.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.